Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients

A single dose of bevacizumab reduced the density of angiopoietin-2-positive vessels while improving the infiltration of CD4+ T and CD8+ T cells, and mature dendritic cells in patients with primary triple-negative breast cancer. Our findings provide a rationale for including bevacizumab during neoadjuvant treatment to enhance the efficacy of immune checkpoint blockers in this disease.

Automated summary

The study showed that a single dose of bevacizumab can reduce the density of angiopoietin-2-positive vessels and increase the infiltration of immune cells in patients with primary triple-negative breast cancer, suggesting a potential rationale for combining bevacizumab with immune checkpoint blockers in neoadjuvant treatment to improve efficacy.